RHÖN-KLINIKUM AG  / Key word(s): Share Buyback

14.10.2014 21:36

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.



With the approval of the audit committee of the supervisory board, the
management board of RHÖN-KLINIKUM AG today resolved to make a public
repurchase offer pursuant to item 3 of the agenda of the annual general
meeting of 12 June 2014 for the repurchase of up to 65,813,330 shares
outside the stock exchange.

The offer price per share (excluding ancillary purchase costs) paid by the
Company amounts to EUR 25.18.The offer price includes a premium of 7% on
the reference stock quote of EUR 23.54 which is the average stock market
price at the Frankfurt Stock Exchange on the last three trading days before
29 April 2014 as day of the first public announcement of the share
repurchase.

The period for the acceptance of the repurchase offer of the Company
commences on 16 October 2014, 0:00 hrs. (Central European Summer Time), and
ends, unless prolonged, on 14 November 2014, 24:00 hrs. (Central European
Time).

The tender ratio for this repurchase offer is 21:10, the ownership of 21
shares thus entitles a shareholder to accept the repurchase offer for 10
shares. The shareholders shall be entitled to corresponding tender rights,
in each case with one share containing one tender right and 21 tender
rights being required to accept the repurchase offer for 10 shares.

To the extent shareholders should wish not to participate in the share
repurchase, they can sell their tender rights. Likewise, shareholders may
purchase additional tender rights if they would like to tender more shares.

The tender rights will be admitted to trading on the regulated market of
the Frankfurt Stock Exchange with simultaneous admission to the sub area
with additional post-admission obligations (Prime Standard) and be tradable
there dated 16 October 2014 until two banking days before the end of the
acceptance period. An off-market transfer of the tender rights is also
permissible and possible.

Baader Bank AG will be the financial institution accompanying the share
repurchase.

According to the resolution of the annual general meeting, repurchased
shares may only be used by the Company for the purpose of redemption and
subsequent reduction of the share capital.

Further details on the public repurchase offer can be found in the offer
document of the Company which will be published in the Federal Gazette
(www.bundesanzeiger.de) and in the German and the English language together
with additional information on the website of the Company (German version:
www.rhoen-klinikum-ag.com/aktie; English version:
www.rhoen-klinikum-ag.com/share).

Contact:

Dr. Kai G. Klinger
Head of Investor Relations
RHÖN-KLINIKUM AG
Schlossplatz 1
97616 Bad Neustadt a. d. Saale
Telefon: +49 (0) 9771 65-1318
Telefax: +49 (0) 9771 99-1736
E-Mail: ir@rhoen-klinikum-ag.com

Achim Struchholz
Head of Corporate Communications
RHÖN-KLINIKUM AG
Schlossplatz 1
97616 Bad Neustadt a. d. Saale
Telefon: +49 (0) 9771 65-1327
Telefax: +49 (0) 9771 65-1820
E-Mail: kommunikation@rhoen-klinikum-ag.com 


14.10.2014 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de


 
Language:     English
Company:      RHÖN-KLINIKUM AG
              Schlossplatz 1
              97616 Bad Neustadt a.d.Saale
              Germany
Phone:        +49 (0)9771 - 65-0
Fax:          +49 (0)9771 - 97 467
E-mail:       rka@rhoen-klinikum-ag.com
Internet:     www.rhoen-klinikum-ag.com
ISIN:         DE0007042301
WKN:          704230
Indices:      MDAX
Listed:       Regulierter Markt in Frankfurt (Prime Standard), München;
              Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart
 
End of Announcement                             DGAP News-Service